ArticleBiological research2026
From in vitro to in vivo: hypoxia attenuates replicative senescence and preserves therapeutic activity in long-term passaged human umbilical cord-derived mesenchymal stem cells.
Article in Biological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) hold great potential for regenerative medicine and tissue engineering. However, their clinical use is limited by low in vivo availability and rapid senescence during ex vivo expansion, posing a major challenge for scaled production. Growing evidence indicates that microenvironmental oxygen tension critically regulates MSCs fate. This study aims to systematically evaluate how different oxygen tensions modulate MSCs aging and function, providing evidence to optimize MSCs expansion protocols for clinical applications.
methodsHuman umbilical cord derived-mesenchymal stem cells (hUC-MSCs) were maintained under normoxic (20%O
resultsCells cultured under both 20%O
conclusionWe provide the first in vivo evidence that hypoxic culture conditions enables high-passage hUC-MSCs(P16) to retain therapeutic potency in diabetic nephropathy. Our findings demonstrate that hypoxia effectively mitigates replicative senescence through suppression of oxidative damage and SASP secretion, thereby preserving the proliferative capacity and paracrine repair functions of long-term cultured cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.